T2DM as defined by American Diabetes Association (ADA) criteria
Adult patients with T2DM who are indicated to receive liraglutide, not as first-line therapy, in addition to diet and exercise to improve glycemic control
Hemoglobin A1c (HbA1c) = 9%
Age = 18 years old
Body mass index (BMI) = 27 Kg/m2 and/or waist circumference = 102 cm (40 inches) in men and 88 cm (35 inches) in women, respectively.
Clinically and angiographically stable CAD who requires CABG as part of the standard medical care, as CAD does not represent a contraindication for using liraglutide. The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutide

NCT03260881_inc_T1
Condition
T2DM
NCT03260881_inc_T2
Qualifier
American Diabetes Association (ADA) criteria
NCT03260881_inc_T3
Person
Adult
NCT03260881_inc_T4
Condition
T2DM
NCT03260881_inc_T5
Drug
liraglutide
NCT03260881_inc_T6
Mood
indicated to receive
NCT03260881_inc_T7
Qualifier
first-line therapy
NCT03260881_inc_T8
Negation
not
NCT03260881_inc_T10
Measurement
Hemoglobin A1c (HbA1c)
NCT03260881_inc_T11
Value
= 9%
NCT03260881_inc_T12
Person
Age
NCT03260881_inc_T13
Value
= 18 years old
NCT03260881_inc_T14
Measurement
Body mass index (BMI)
NCT03260881_inc_T15
Value
= 27 Kg/m2
NCT03260881_inc_T16
Measurement
waist circumference
NCT03260881_inc_T17
Value
= 102 cm
NCT03260881_inc_T18
Value
40 inches
NCT03260881_inc_T19
Person
men
NCT03260881_inc_T20
Value
88 cm
NCT03260881_inc_T21
Value
35 inches
NCT03260881_inc_T22
Person
women
NCT03260881_inc_T23
Scope
= 102 cm (40 inches) in men and 88 cm (35 inches) in women
NCT03260881_inc_T24
Qualifier
angiographically stable
NCT03260881_inc_T25
Condition
CAD
NCT03260881_inc_T26
Procedure
CABG
NCT03260881_inc_T27
Mood
requires
NCT03260881_inc_T28
Qualifier
cally and e CAD